Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000973 · ClinicalTrials.gov registry record · Phase 1
A Study of Pyrimethamine in the Treatment of Infection by a Certain Parasite in HIV-Positive Patients
A Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT00000973 is a Phase 1 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 26 participants.
The verdict
NCT00000973, a Phase 1 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
To determine the manner in which pyrimethamine is metabolized and excreted in patients currently receiving zidovudine (AZT). An important goal of this measurement is to establish the optimal dose of pyrimethamine necessary to prevent the development of toxoplasmosis in AIDS patients or delay the subsequent return of toxoplasmic encephalitis. Encephalitis caused by Toxoplasma gondii has emerged as the most frequent cause of focal central nervous system infection in patients with AIDS. Untreated, the encephalitis is fatal. The best treatment for this disease has not been determined. Presently it is standard practice to administer a combination of pyrimethamine and sulfadiazine. Little is known about the pharmacokinetics of pyrimethamine in patients with AIDS receiving AZT. Furthermore, there are reports that patients already exposed to toxoplasmosis may not have uniform absorption of pyrimethamine.
Interventions
- DRUG Zidovudine
- DRUG Leucovorin calcium
- DRUG Pyrimethamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Est. Completion | 1995-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00000973
The ClinicalTrials.gov registry entry for NCT00000973 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Zidovudine is the first listed.
NCT00000973 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00000973 about?
NCT00000973 is a clinical study titled "A Study of Pyrimethamine in the Treatment of Infection by a Certain Parasite in HIV-Positive Patients". To determine the manner in which pyrimethamine is metabolized and excreted in patients currently receiving zidovudine (AZT). An important goal of this measurement is to establish the optimal dose of pyrimethamine necessary to prevent the development of toxoplasmosis in AIDS patients or delay the sub...
What is the current status of trial NCT00000973?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. Estimated completion is 1995-03.
What interventions are being tested in trial NCT00000973?
The interventions under investigation include: Zidovudine (DRUG), Leucovorin calcium (DRUG), Pyrimethamine (DRUG).
Who is sponsoring clinical trial NCT00000973?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.